ADGRG2 and congenital bilateral aplasia of vas deferens from CFTR mutation: Considering that the genetic factors of approximately 30% of CBAVD patients remain unknown, it is recommended to perform massive parallel sequencing for patients who test negative for CFTR and ADGRG2 gene screening.